

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**April 7, 2020**

---

**I Continuing Review**

**10150**, A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer (Protocol Version Date 02/15/19)

---

**II Continuing Review**

**10220**, A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors (Protocol Version Date 11/21/19)

---

**III Amendment**

**EAY131**, Molecular Analysis for Therapy Choice (MATCH) (Protocol Version Date 02/28/20)

---